Knight Therapeutics Inc. has announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency. This submission marks a significant step in Knight's effort to expand its neurology portfolio and address the high unmet medical needs in the treatment of Parkinson's disease. CREXONT® is a novel, extended-release oral formulation of carbidopa/levodopa, intended for the treatment of Parkinson's disease and other related conditions. The application in Mexico follows a similar submission in Canada, where Health Canada has accepted CREXONT® for review. Knight Therapeutics holds the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America through an agreement with Amneal Pharmaceuticals, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.